BE Pharmaceuticals Private Ltd. – FDA 483, Jun 12, 2014
This FDA Form 483 report details significant data integrity and quality control failures at Akorn India PVT, a sterile drug product manufacturer in Paonta Sahib, India. Inspectors found widespread falsification of laboratory testing records for sterility, water analysis, environmental monitoring, biological indicators, bioburden, bacterial endotoxins, and media fills. Additionally, the firm exhibited inadequate personnel training, poor change control, uninvestigated discrepancies, and deficiencies in laboratory controls, facility design, document control, warehousing, and equipment cleaning.
ID · e397dc36-949c-4002-8381-db4e30258acf
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.